行情

RETA

RETA

Reata制药
NASDAQ

实时行情|Nasdaq Last Sale

141.19
+3.77
+2.74%
盘后: 141.19 0 0.00% 16:28 04/09 EDT
开盘
139.71
昨收
137.42
最高
144.29
最低
137.25
成交量
26.70万
成交额
--
52周最高
257.97
52周最低
70.00
市值
46.92亿
市盈率(TTM)
-15.1060
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RETA价格均价为275.50,最高价位335.00,最低价为172.00。

EPS

RETA 新闻

更多
  • AppAnnie发布声明:拼多多相关数据还需校验,此前排名报道已撤回
  • 36氪 · 1小时前
  • 白俄罗斯总理建议欧亚经济联盟大力推动去美元化进程
  • 央视 · 2小时前
  • 摩根大通大幅下调对美国经济前景的预期
  • 新浪财经综合 · 2小时前
  • 2.3万亿美元并非最后一搏,美联储还能继续放水!
  • 新浪财经综合 · 2小时前

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.82%

热门股票

代码
价格
涨跌幅

RETA 简况

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
展开

微牛提供Reata Pharmaceuticals Inc(NASDAQ-RETA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RETA股票新闻,以帮助您做出投资决策。